-
Je něco špatně v tomto záznamu ?
Inhibition of Lipolysis Ameliorates Diabetic Phenotype in a Mouse Model of Obstructive Sleep Apnea
M. Weiszenstein, LA. Shimoda, M. Koc, O. Seda, J. Polak,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 1997-07-01 do Před 1 rokem
ProQuest Central
od 1994-01-01 do Před 9 měsíci
ProQuest Central
od 2011-01-01 do 2019-09-30
Health & Medicine (ProQuest)
od 2011-01-01 do 2019-09-30
PubMed
26978122
DOI
10.1165/rcmb.2015-0315oc
Knihovny.cz E-zdroje
- MeSH
- adipozita účinky léků MeSH
- experimentální diabetes mellitus krev komplikace genetika patologie MeSH
- fenotyp MeSH
- glukosa metabolismus MeSH
- hypoxie komplikace metabolismus MeSH
- inzulin metabolismus MeSH
- lipolýza * účinky léků MeSH
- mastné kyseliny krev MeSH
- modely nemocí na zvířatech MeSH
- myši inbrední C57BL MeSH
- obstrukční spánková apnoe krev komplikace genetika patologie MeSH
- pyraziny farmakologie MeSH
- regulace genové exprese účinky léků MeSH
- signální transdukce účinky léků MeSH
- tukové buňky účinky léků patologie MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Obstructive sleep apnea (OSA) is associated with insulin resistance, glucose intolerance, and type 2 diabetes. Causal mechanisms mediating this association are not well defined; however, augmented lipolysis in adipose might be involved. Here, we investigated the effect of acipimox treatment (lipolysis inhibitor) on glucose tolerance and insulin sensitivity in mice exposed to intermittent hypoxia (IH). C57BL6/J mice were exposed for 14 days to IH or control conditions. IH was created by decreasing the fraction of inspired oxygen from 20.9 to 6.5%, 60 times/h. Control exposure was air (fraction of inspired oxygen, 20.9%) delivered at an identical flow rate. Acipimox was provided in drinking water (0.5 g/ml) during exposures. After exposures, intraperitoneal insulin (0.5 IU/kg) and glucose (1 g/kg) tolerance tests were performed, and primary adipocytes were isolated for lipolysis experiments. IH elevated fasting glucose by 51% and worsened glucose tolerance and insulin sensitivity by 33 and 102%, respectively. In parallel, IH increased spontaneous lipolysis by 264%, and reduced epididymal fat mass by 15% and adipocyte size by 8%. Acipimox treatment prevented IH-induced lipolysis and increased epididymal fat mass and adipocyte size by 19 and 10%, respectively. Acipimox fully prevented IH-induced impairments in fasting glycemia, glucose tolerance, and insulin sensitivity. For all reported results, P less than 0.05 was considered significant. Augmented lipolysis contributes to insulin resistance and glucose intolerance observed in mice exposed to IH. Acipimox treatment ameliorated the metabolic consequences of IH and might represent a novel treatment option for patients with obstructive sleep apnea.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031827
- 003
- CZ-PrNML
- 005
- 20171030102214.0
- 007
- ta
- 008
- 171025s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1165/rcmb.2015-0315OC $2 doi
- 035 __
- $a (PubMed)26978122
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Weiszenstein, Martin $u 1 Center for Research on Diabetes, Metabolism, and Nutrition, Third Faculty of Medicine. 2 Center of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic.
- 245 10
- $a Inhibition of Lipolysis Ameliorates Diabetic Phenotype in a Mouse Model of Obstructive Sleep Apnea / $c M. Weiszenstein, LA. Shimoda, M. Koc, O. Seda, J. Polak,
- 520 9_
- $a Obstructive sleep apnea (OSA) is associated with insulin resistance, glucose intolerance, and type 2 diabetes. Causal mechanisms mediating this association are not well defined; however, augmented lipolysis in adipose might be involved. Here, we investigated the effect of acipimox treatment (lipolysis inhibitor) on glucose tolerance and insulin sensitivity in mice exposed to intermittent hypoxia (IH). C57BL6/J mice were exposed for 14 days to IH or control conditions. IH was created by decreasing the fraction of inspired oxygen from 20.9 to 6.5%, 60 times/h. Control exposure was air (fraction of inspired oxygen, 20.9%) delivered at an identical flow rate. Acipimox was provided in drinking water (0.5 g/ml) during exposures. After exposures, intraperitoneal insulin (0.5 IU/kg) and glucose (1 g/kg) tolerance tests were performed, and primary adipocytes were isolated for lipolysis experiments. IH elevated fasting glucose by 51% and worsened glucose tolerance and insulin sensitivity by 33 and 102%, respectively. In parallel, IH increased spontaneous lipolysis by 264%, and reduced epididymal fat mass by 15% and adipocyte size by 8%. Acipimox treatment prevented IH-induced lipolysis and increased epididymal fat mass and adipocyte size by 19 and 10%, respectively. Acipimox fully prevented IH-induced impairments in fasting glycemia, glucose tolerance, and insulin sensitivity. For all reported results, P less than 0.05 was considered significant. Augmented lipolysis contributes to insulin resistance and glucose intolerance observed in mice exposed to IH. Acipimox treatment ameliorated the metabolic consequences of IH and might represent a novel treatment option for patients with obstructive sleep apnea.
- 650 _2
- $a tukové buňky $x účinky léků $x patologie $7 D017667
- 650 _2
- $a adipozita $x účinky léků $7 D050154
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a experimentální diabetes mellitus $x krev $x komplikace $x genetika $x patologie $7 D003921
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a mastné kyseliny $x krev $7 D005227
- 650 _2
- $a regulace genové exprese $x účinky léků $7 D005786
- 650 _2
- $a glukosa $x metabolismus $7 D005947
- 650 _2
- $a hypoxie $x komplikace $x metabolismus $7 D000860
- 650 _2
- $a inzulin $x metabolismus $7 D007328
- 650 12
- $a lipolýza $x účinky léků $7 D008066
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a fenotyp $7 D010641
- 650 _2
- $a pyraziny $x farmakologie $7 D011719
- 650 _2
- $a signální transdukce $x účinky léků $7 D015398
- 650 _2
- $a obstrukční spánková apnoe $x krev $x komplikace $x genetika $x patologie $7 D020181
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Shimoda, Larissa A $u 3 Division of Pulmonary and Critical Care Medicine, Asthma and Allergy Center, Johns Hopkins School of Medicine, Baltimore, Maryland.
- 700 1_
- $a Koc, Michal $u 4 Sports Medicine Department, Third Faculty of Medicine, and.
- 700 1_
- $a Seda, Ondrej $u 5 Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; and.
- 700 1_
- $a Polak, Jan $u 1 Center for Research on Diabetes, Metabolism, and Nutrition, Third Faculty of Medicine. 2 Center of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic. 3 Division of Pulmonary and Critical Care Medicine, Asthma and Allergy Center, Johns Hopkins School of Medicine, Baltimore, Maryland. 6 Second Internal Medicine Department, Vinohrady Teaching Hospital, Prague, Czech Republic.
- 773 0_
- $w MED00000298 $t American journal of respiratory cell and molecular biology $x 1535-4989 $g Roč. 55, č. 2 (2016), s. 299-307
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26978122 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171030102303 $b ABA008
- 999 __
- $a ok $b bmc $g 1255420 $s 992854
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 55 $c 2 $d 299-307 $i 1535-4989 $m American journal of respiratory cell and molecular biology $n Am J Respir Cell Mol Biol $x MED00000298
- LZP __
- $a Pubmed-20171025